OraSure Technologies, Inc. Logo
OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver
September 23, 2021 08:10 ET | OraSure Technologies, Inc.
BETHLEHEM, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies,...
Celldex Logo.jpg
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
September 23, 2021 08:01 ET | Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase...
Point.JPG
POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC
September 23, 2021 08:00 ET | POINT Biopharma
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS,...
Reservoir Logo Hi Res.jpg
Reservoir Applauds Agreement Between National Music Publishers’ Association and Twitch
September 23, 2021 08:00 ET | Reservoir Media, Inc.
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Reservoir Media, Inc. (NASDAQ: RSVR) (“Reservoir” or the “Company”), an award-winning independent music company, today applauded the new agreement...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
September 23, 2021 08:00 ET | Daré Bioscience, Inc.
Investigational therapy for women who cannot, or should not, take supplemental estrogen Potential to be the first treatment for vulvar and vaginal atrophy specifically developed for patients with...
BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com
September 23, 2021 08:00 ET | Briacell Therapeutics Corp.
AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq:...
nano-logo (002).jpg
Nanox to Present at the Cantor Fitzgerald Global Healthcare Conference
September 23, 2021 08:00 ET | Nano-X Imaging
NEVE ILAN, Israel, Sept. 23, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that Nanox’s...
Exela-826x374.png
Exela Technologies Expands Electronic Signature Platform, DrySign, to the UK
September 23, 2021 08:00 ET | Exela Technologies, Inc.
IRVING, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA) today announced the launch of its comprehensive electronic signature solution, DrySign®, in the UK...
Exela-826x374.png
Exela Technologies Expands Electronic Signature Platform, DrySign, to the UK
September 23, 2021 08:00 ET | Exela Technologies, Inc.
LONDON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA) today announced the launch of its comprehensive electronic signature solution, DrySign®, in the UK...
Unknown.png
TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation
September 23, 2021 08:00 ET | TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...